Ture or False: Patients with established atherosclerosis or diabetes, cardiovascular risk factors, and triglyceride levels greater than or equal to 135 mm/dL who are receiving the highest levels of on-treatment eicosapentaenoic acid (EPA) will likely experience an increase in new heart failure and hospitalization for heart failure.
“In the overall REDUCE-IT trial, there was a numerically lower rate of heart failure, but this wasn’t statistically significant. However, in these EPA analyses, we see that patients at the highest levels of on-treatment EPA, there was indeed a significant reduction in new heart failure and hospitalization for heart failure,” said Dr Bhatt. “Thus, we see in REDUCE-IT EPA, the full extent of ischemic events and now also heart failure are significantly correlated with higher levels of on-treatment EPA.”
Watch Dr Bhatt provide insight into the results in this video. Or read the video transcript here.